ROCHESTER, Mich., May 02, 2018 -- OptimizeRx Corp. (OTCQB:OPRX), the nation’s leading provider of digital health messaging for the pharmaceutical industry, has entered into a definitive agreement with two institutional investors and a large family office for a private offering of common stock.
OptimizeRx will issue 5 million shares of its common stock to the investors at $1.80 per share, resulting in aggregate gross proceeds of $9 million to the company. The company intends to use the proceeds for general corporate purposes.
“Our record Q1 results demonstrate the strong momentum in our business, including growth in pharma brands, channel partners, and healthcare providers on the OptimizeRx network,” said OptimizeRx CEO, William Febbo. “We expect to use some of the proceeds from this capital raise to fund additional sales and channel investments in our core ambulatory market, where we continue to demonstrate high ROI for our pharma clients’ marketing spend. It will also support our further expansion into the hospital channel, which represents a significant growth opportunity.”
Lake Street Capital Markets is acting as the sole placement agent, with B. Riley FBR acting as an advisor to the transaction.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About OptimizeRx
OptimizeRx® (OTCQB:OPRX) is the nation’s leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company’s cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, education, and critical clinical information. The company’s network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half of the ambulatory market access to these benefits within their workflow at the point of care. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
OptimizeRx Contact:
Doug Baker, CFO
Tel (248) 651-6568 x807
[email protected]
Investor Relations Contact:
Ron Both, CMA
Tel (949) 432-7557
[email protected]


Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 



